Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected to be pivotal for product registration in ChinaFirst patient in the study will trigger a milestone payment to...

Adocia在1型糖尿病患者中启动BC LisPram通过泵给药的1期临床试验 首次在单个泵中测试与血糖控制相关的两个关键激素，即速效胰岛素类似物和淀粉类似物的独特组合，BioChaperone® 赖脯胰岛素和普兰林肽联合制剂的安全性、药代动力学和血糖控制能力将与赖脯胰岛素进行比较 里昂, June 30, 2021 (GLOBE NEWSWIRE) -- Adocia (巴黎泛欧交易所: FR0011184241 – ADOC),...

Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes For the first time, a unique combination of two key hormones involved in glycemic control, a rapid acting insulin analog and an amylin analog, is tested in a single pumpBioChaperone® Lispro and...